Oxford Biomedica (OXB) RNS Announcements

Add to Alert list
Date Time Source Announcement
29 Jun 2012 07:00 AM
RNS
US$3 million Option Exercise Payment from Sanofi
21 Jun 2012 11:31 AM
RNS
Holding(s) in Company
08 Jun 2012 07:00 AM
RNS
MHRA Approval for Manufacturing Facility
07 Jun 2012 03:00 PM
RNS
Result of AGM
11 May 2012 07:00 AM
RNS
Interim Management Statement
08 May 2012 07:00 AM
RNS
Presentation of Ocular Clinical Data at ARVO
27 Apr 2012 12:30 PM
RNS
2011 Annual Report and Accounts & AGM Notification
17 Apr 2012 02:00 PM
RNS
Annual Information Update
16 Apr 2012 07:00 AM
RNS
Successful Completion of Phase I/II Study
22 Mar 2012 09:57 AM
RNS
TR-1 Notification of Major Interest in Shares
12 Mar 2012 07:00 AM
RNS
SIGNIFICANT SHAREHOLDING
08 Mar 2012 07:00 AM
RNS
Director / PDMR dealings
06 Mar 2012 07:00 AM
RNS
Preliminary Results
24 Feb 2012 07:00 AM
RNS
Notice of Results
10 Feb 2012 07:00 AM
RNS
Management and Board change
30 Jan 2012 11:51 AM
RNS
Notification of Major Interest in Shares
16 Dec 2011 07:00 AM
RNS
Directors' Interest in Shares
15 Dec 2011 07:00 AM
RNS
Interim Update on ProSavin? Phase I/II Study
05 Dec 2011 04:35 PM
RNS
Price Monitoring Extension
28 Nov 2011 07:00 AM
RNS
Block Listing Six Monthly Return
16 Nov 2011 07:00 AM
RNS
Interim Management Statement
18 Oct 2011 07:00 AM
RNS
US IND Approval for Novel Ocular Product
04 Oct 2011 04:39 PM
RNS
TR1 Form
04 Oct 2011 04:32 PM
RNS
TR1 Form
31 Aug 2011 09:00 AM
RNS
TR-1: Notification of Major Interest in Shares
31 Aug 2011 08:18 AM
RNS
Interim Results- Replacement
31 Aug 2011 07:00 AM
RNS
Interim Results
04 Aug 2011 04:35 PM
RNS
Price Monitoring Extension
04 Aug 2011 07:00 AM
RNS
Interim Data from ProSavin? Phase I/II Study
08 Jul 2011 09:12 AM
RNS
Holding(s) in Company
28 Jun 2011 07:00 AM
RNS
Notice of Results
07 Jun 2011 07:00 AM
RNS
Research Agreement with ImaginAb
26 May 2011 07:00 AM
RNS
Block Listing Six Monthly Return
24 May 2011 07:00 AM
RNS
Management and Board Changes
23 May 2011 07:00 AM
RNS
NEW CLINICAL DATA FROM PROSAVIN? PHASE I/II STUDY
19 May 2011 04:40 PM
RNS
Second Price Monitoring Extn
19 May 2011 04:35 PM
RNS
Price Monitoring Extension
18 May 2011 07:00 AM
RNS
Interim Management Statement
05 May 2011 12:54 PM
RNS
Annual General Meeting and Board Changes
04 May 2011 07:00 AM
RNS
Pfizer License Extension
03 May 2011 07:00 AM
RNS
Announcement of Data in ProSavin Study
15 Apr 2011 01:04 PM
RNS
Directors' Interest in Shares and Share Options
14 Apr 2011 04:40 PM
RNS
Second Price Monitoring Extn
14 Apr 2011 04:35 PM
RNS
Price Monitoring Extension
04 Apr 2011 10:28 AM
RNS
Annual Information Update
31 Mar 2011 07:12 AM
RNS
Annual Report and Accounts & AGM Notification
22 Mar 2011 07:00 AM
RNS
Director/PDMR Shareholding
21 Mar 2011 07:01 AM
RNS
Directorate Change
21 Mar 2011 07:00 AM
RNS
StarGen US IND Approval
02 Mar 2011 07:00 AM
RNS
PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2010

Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.

Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.

Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.

UK 100